Edurne Mugarza

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Journal: Science advances
Published: November 01, 2024

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

Journal: Nature communications
Published: January 23, 2024

CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

Journal: Cancer research
Published: August 30, 2023

CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes.

CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes.

Journal: Nature communications
Published: August 17, 2023

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Journal: Science advances
Published: July 20, 2022

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.

Journal: Cancer research
Published: January 28, 2022

Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.

Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.

Journal: Nature communications
Published: March 05, 2021

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.

Journal: Science translational medicine
Published: February 01, 2019

GLP-1 nanomedicine alleviates gut inflammation.

GLP-1 nanomedicine alleviates gut inflammation.

Journal: Nanomedicine : nanotechnology, biology, and medicine
Published: October 02, 2015
Showing 1-9 of 9

Last Updated: 09/26/2026